Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Jun 22, 2011


Harvard University professor and cancer institute director Ronald DePinho has been named the next president of The University of Texas MD Anderson Cancer Center in Houston.

DePinho currently is director of the Belfer Institute for Applied Cancer Science at the Dana-Farber Cancer Institute and he is a professor of medicine and genetics at Harvard. He will take over the position in September for John Mendelsohn, who announced he would step down from the presidency last December. Lynda Chin, DePinho's wife and Belfer's current scientific director, also will join the faculty at MD Anderson.

Sequenom has appointed Beckman Coulter CFO and Senior VP of Finance Charles Slacik to serve on its board of directors. Slacik formerly was executive VP and CFO at Watson Pharmaceuticals and senior VP and CFO at the medical technologies company C.R. Bard. Sequenom said in a US Securities and Exchange Commission filing this week that it has granted Slacik a non-qualified stock option to buy 40,000 shares of the company's common stock at $7.89 per share, the market valuation at the date of the grant, and will provide him with additional compensation.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.